p16-Positive Squamous Cell Carcinoma Treatment Options

Treatment for p16-positive squamous cell carcinoma centers on the oropharynx, where p16 expression serves as a reliable marker for HPV-driven cancer and signals a dramatically better prognosis than its p16-negative counterpart. Five-year overall survival for p16-positive oropharyngeal squamous cell carcinoma (OPSCC) reaches roughly 94%, compared with about 62% for p16-negative cases.¹ That survival gap has reshaped how clinicians stage, treat, and follow these tumors, and it has opened an active debate about whether standard-intensity therapy is more than these patients actually need.

Why p16 Status Changes Everything

In oropharyngeal tumors, p16 protein expression is tightly linked to underlying HPV infection, particularly HPV-16. The protein accumulates when the virus disrupts normal cell-cycle controls, so pathologists use p16 immunohistochemistry as a surrogate marker for HPV-driven disease.² In practical terms, if your biopsy comes back p16-positive and the tumor sits in the oropharynx (the tonsil or base of tongue region), clinicians treat it as HPV-associated cancer. That distinction matters because HPV-driven tumors respond better to radiation and chemotherapy than tumors caused by tobacco and alcohol alone.

The 8th edition of the major cancer staging system (AJCC) created an entirely separate staging framework for p16-positive oropharyngeal cancers, acknowledging that lumping them together with p16-negative tumors was producing misleadingly grim stage assignments. Under the new system, many patients who would have been classified as advanced stage are reclassified to earlier stages, which better predicts their actual outcomes and influences treatment decisions going forward.³

Standard First-Line Treatment

For most patients with locally advanced p16-positive OPSCC who are not candidates for primary surgery, the standard approach remains radiation therapy delivered alongside cisplatin-based chemotherapy. Multiple trials and a meta-analysis have confirmed that cisplatin-based chemoradiation should remain the definitive standard treatment for these cancers.⁴ This typically involves about seven weeks of daily radiation with concurrent cisplatin infusions. Cisplatin is effective but hard on the body: nausea, kidney stress, hearing changes, and severe fatigue are common side effects. The good news is that the tumor control rates are high enough that survival outcomes are excellent for most patients.

Importantly, the favorable prognosis associated with p16 positivity applies most clearly to patients who achieve a complete response to treatment. One study found that p16-positive status predicted better outcomes specifically among complete responders, but not among patients whose tumors failed to respond fully.⁵ The message: p16 positivity is a strong prognostic marker, but it does not guarantee a good outcome for every individual.

Transoral Robotic Surgery as a Primary Option

Surgery has re-emerged as a leading upfront treatment for many p16-positive oropharyngeal cancers, thanks largely to transoral robotic surgery (TORS). Rather than making external incisions through the jaw or neck, the surgeon operates through the mouth using a robotic platform. Compared to older open surgical techniques, TORS delivers better functional outcomes in speech and swallowing while maintaining strong tumor control.⁶

Oncologic results with TORS in HPV-positive patients have been encouraging. One series of HPV/p16-positive patients treated with TORS reported five-year locoregional control of 98%, distant metastasis-free survival of 96%, and disease-specific survival of 100%.⁷ Even in older patients, who historically have been considered higher risk, TORS yields strong results: three-year overall survival around 90% and disease-specific survival above 92%.⁸

A key advantage of starting with surgery is that the pathology from the removed specimen can guide what comes next. Some patients with favorable surgical findings may be spared chemotherapy entirely and receive only radiation afterward, or in select low-risk cases, may be observed closely without any adjuvant treatment at all.

Why Cetuximab Fell Short

Because cisplatin is toxic, researchers spent years testing whether a gentler drug called cetuximab (a targeted antibody) could replace it alongside radiation for p16-positive patients. The hope was that these good-prognosis tumors did not need such aggressive chemotherapy. That hope did not hold up.

Two landmark trials delivered clear verdicts. The De-ESCALaTE trial found that patients receiving cetuximab plus radiation had significantly worse two-year overall survival compared with those receiving cisplatin plus radiation: about 89% versus 97%. Recurrence rates were also substantially higher in the cetuximab arm. Cetuximab showed no benefit in reduced toxicity to offset its poorer tumor control.⁹ A separate trial (RTOG 1016) confirmed these findings, showing that cetuximab did not meet the bar for non-inferiority to cisplatin, with five-year overall survival of about 78% versus 85% and more than double the rate of locoregional failure.¹⁰

Mature data from yet another trial (ARTSCAN III) has reinforced the same conclusion, showing five-year overall survival of 82% with cisplatin versus 71% with cetuximab.¹¹ The lesson from these trials is unambiguous: for patients who can tolerate cisplatin, swapping it for cetuximab worsens outcomes. Cetuximab remains an option only for patients who genuinely cannot receive cisplatin due to kidney disease, hearing loss, or other contraindications.

De-escalation Through Reduced Radiation

While drug substitution failed, a different de-escalation approach is showing more promise: reducing the radiation dose and treatment volume. Standard radiation for head and neck cancer involves treating a broad area at high doses, which causes significant long-term side effects including chronic dry mouth, difficulty swallowing, and tissue scarring. Because p16-positive tumors respond so well to treatment, investigators have asked whether you can dial down the radiation without sacrificing tumor control.

A large cohort study of 276 patients with locally advanced HPV-positive OPSCC tested substantial dose reduction to the lower-risk areas of the neck while maintaining full dose to the primary tumor. At two years, locoregional control was 97% and overall survival was about 95%, suggesting that major de-escalation in the elective (preventive) radiation regions was feasible.¹² A systematic review and meta-analysis across multiple studies confirmed that reduced-dose radiation significantly lowered treatment toxicity and improved quality of life while maintaining favorable cancer control.¹³

The practical benefits of dose reduction are real. In one phase 2 de-escalation study, dry mouth was common but mostly mild, severe side effects were rare over three years of follow-up, no patients became permanently dependent on a feeding tube, and swallowing function improved within a year of completing treatment. Quality of life scores returned to baseline for most patients.¹⁴ Radiation de-escalation remains investigational in many settings, but it is one of the most active and promising areas of clinical trial work for this disease.

Tailoring Adjuvant Treatment After Surgery

After TORS or other surgical removal, the pathology results determine what additional treatment, if any, is needed. Traditionally, features like positive surgical margins or cancer spreading outside the lymph node capsule (extranodal extension) trigger aggressive adjuvant therapy combining radiation with chemotherapy. But for p16-positive tumors, this conventional wisdom is being questioned.

A study comparing adjuvant radiation alone versus radiation plus chemotherapy in p16-positive patients with those high-risk features (positive margins or extranodal extension) found no significant survival difference between the two approaches.¹⁵ Another analysis found that adding chemotherapy to adjuvant radiation in surgically treated p16-positive patients was not associated with improved disease-free survival, and it pointed toward a possible increase in overall mortality.¹⁶ These findings do not mean adjuvant chemotherapy is never indicated, but they fuel the argument that many p16-positive patients are being overtreated after surgery, absorbing chemotherapy’s side effects without clear survival benefit.

How Smoking Complicates the Picture

If you smoke and have p16-positive oropharyngeal cancer, the expected survival advantage shrinks considerably. Among non-smokers, HPV-positive status was associated with about an 85% lower risk of death compared with HPV-negative non-smokers. Among smokers, that protective effect was largely erased.¹⁷ Heavier smoking histories carry progressively worse outcomes: five-year overall survival dropped from about 73% with a ten-pack-year history to roughly 59% with a thirty-pack-year history.¹⁸

This has direct implications for the de-escalation conversation. Most de-escalation trials require low smoking histories as an eligibility criterion, and smoking status is a key variable in risk stratification models used to decide who qualifies for less-intensive therapy. If you are a heavy smoker with p16-positive disease, your oncologist is less likely to recommend reduced-intensity treatment.

There is a wrinkle, though. At least one study looking specifically at HPV-positive patients treated with TORS found that smoking history was not significantly associated with recurrence-free survival, with similar outcomes between never, former, and current smokers. The authors argued against excluding smokers with early-stage HPV-positive disease from surgical de-intensification trials.¹⁹ This discrepancy may relate to the fact that surgical patients tend to have earlier-stage disease where the tumor biology matters less than whether the surgeon gets clean margins. The bottom line: smoking is clearly detrimental overall, but the magnitude of its effect may depend on the treatment pathway and stage of disease.

Immunotherapy for Recurrent or Metastatic Disease

When p16-positive oropharyngeal cancer recurs or spreads despite initial treatment, immune checkpoint inhibitors have become a cornerstone of care. Nivolumab, an anti-PD-1 antibody, was the first to demonstrate a survival advantage over standard chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma, extending median overall survival from about five months to seven and a half months and roughly doubling the one-year survival rate.²⁰ Pembrolizumab, a similar drug, has also shown comparable activity.²¹

Part of why immunotherapy works in these tumors ties back to biology. HPV-positive oropharyngeal cancers tend to have a more “inflamed” tumor microenvironment, with higher levels of tumor-infiltrating immune cells, more active antigen-presentation machinery, and greater expression of the checkpoint molecules that drugs like nivolumab are designed to block.²² Transcriptomic analysis has confirmed that p16-positive tumors show higher lymphoid compartment and antigen presentation activity compared with their p16-negative counterparts.²³ In short, the immune system is already trying to fight these tumors, and immunotherapy helps remove the brakes.

Salvage Options When Cancer Recurs Locally

Locoregional recurrence after initial treatment is uncommon in p16-positive disease, but when it happens, salvage therapy can still offer meaningful disease control. In one study, local recurrences treated predominantly with salvage surgery yielded a two-year overall survival of about 77%.²⁴ That said, not all recurrences respond equally well to salvage. Patients who had already received adjuvant chemoradiation as their initial treatment, or those with recurrences in certain anatomical locations such as retropharyngeal nodes, tended to have worse outcomes after salvage therapy.²⁵

The choice between salvage surgery, re-irradiation, and systemic therapy depends on where the recurrence appears, what treatment was given initially, and whether the patient can tolerate additional surgery or radiation to a previously treated area. These decisions are complex and highly individualized.

Surveillance With Circulating Tumor DNA

One advantage unique to HPV-positive oropharyngeal cancer is the availability of a blood-based surveillance tool. Because these tumors shed fragments of HPV DNA into the bloodstream, a simple blood draw can detect circulating tumor HPV DNA (ctHPVDNA) and flag recurrence months before it shows up on imaging.

In a study of over 100 patients, those whose ctHPVDNA remained undetectable at all post-treatment time points had a 100% negative predictive value: none developed recurrence. When two consecutive blood tests came back positive, the positive predictive value for biopsy-proven recurrence was 94%, with a median lead time of nearly four months before the recurrence was confirmed by other means.²⁶ Another study reported sensitivity of 100% and specificity above 98% for detecting recurrence during follow-up.²⁷

This biomarker is still being validated for widespread clinical adoption, but it represents a promising shift toward less invasive, more sensitive monitoring.²⁸ For patients, the practical appeal is obvious: a blood test that catches recurrence early, potentially before symptoms develop, and that could eventually reduce the need for frequent imaging scans.

When p16 Does Not Mean What You Think

Everything described above applies specifically to oropharyngeal cancers. Outside the oropharynx, p16 expression does not reliably signal HPV-driven disease and does not carry the same favorable prognosis. This is one of the most important distinctions in head and neck oncology, and one that patients sometimes misunderstand.

In cutaneous (skin) squamous cell carcinoma of the head and neck, for example, roughly a third of tumors stain positive for p16, yet HPV DNA is often undetectable. One study of over 160 cutaneous head and neck SCCs found p16 expression in about 32% of cases, but HPV in situ hybridization was negative in every single one. And crucially, p16 expression had no association with survival in these skin cancers.²⁹ A separate large study confirmed that p16 status was not prognostic for overall, cancer-specific, or progression-free survival in cutaneous SCC lymph node metastases.³⁰

Making matters more complicated, one study actually found that p16-positive cutaneous SCCs had higher recurrence and metastasis rates than p16-negative ones, the opposite of what happens in the oropharynx.³¹ The takeaway: p16 positivity in a skin cancer or a non-oropharyngeal mucosal cancer should not be interpreted the same way as p16 positivity in a tonsil or tongue-base tumor. It does not justify de-escalated treatment, and it does not predict better outcomes.

Even within the oropharynx, a small subset of tumors test p16-positive but turn out to be HPV-negative on more specific testing such as in situ hybridization. These discordant tumors (about 13% of p16-positive oropharyngeal cancers in one analysis) appear to have worse prognosis than truly HPV-driven p16-positive tumors, which raises concerns about relying on p16 staining alone when considering de-escalation.

A Shifting Patient Population

The demographics of this disease are evolving. HPV-associated oropharyngeal cancer was once considered a disease of middle-aged men in their fifties, but the average age at diagnosis has been climbing. At one institution, the mean age rose from about 55 to 59 years between 2002 and 2016, and the proportion of patients over 65 nearly doubled from 10% to about 20%.³² Data from France has shown a similar pattern, with HPV-positive cases now making up over 57% of oropharyngeal cancers and nearly 30% of patients older than 70.³³

This aging trend matters for treatment decisions. Older patients are more likely to have kidney problems, hearing loss, or cardiovascular conditions that make cisplatin risky. They may tolerate surgery differently. And de-escalation trials, which often enroll relatively young and fit patients, may not fully represent the growing older population now being diagnosed. Meanwhile, HPV vaccination is projected to reduce oropharyngeal cancer incidence substantially in younger age groups by 2045, but it will not affect incidence in people currently over 55, meaning the older cohort is likely to dominate the patient population for decades.³⁴

Therapeutic Vaccines and Future Directions

Prophylactic HPV vaccines prevent infection but do not treat existing cancers. Therapeutic vaccines, designed to train the immune system to attack HPV-infected tumor cells, are being studied as a potential treatment approach for HPV-associated oropharyngeal cancer.³⁵ The idea is appealing: because these tumors express viral proteins that are foreign to the body, they present ready-made targets for immune attack. Several clinical trials are testing therapeutic vaccines either alone or combined with checkpoint inhibitors, though none has yet reached the stage of routine clinical use.

Adoptive cell therapies, which involve engineering a patient’s own immune cells to recognize HPV tumor antigens and then reinfusing them, represent another frontier. These approaches are earlier in development for head and neck cancers than they are for certain blood cancers where they have already gained approval. Whether vaccines, cell therapies, or other novel agents ultimately join the treatment toolkit for p16-positive OPSCC remains an open question, but the biology of these tumors makes them unusually attractive targets for immune-based strategies.